Biomaterial Database

Efficacy of ciprofloxacin in animal models of infection. 1987

V T Andriole

The antibacterial efficacy of some of the newer quinolone antimicrobial agents in general, and ciprofloxacin in particular, in animal models of experimental septic arthritis, burn wound sepsis, empyema, chronic gastroenteritis, granuloma pouch infection, intraabdominal abscess, osteomyelitis, prostatis, sinusitis, urinary tract infection, and severe septicemia caused by Pseudomonas aeruginosa is reviewed. In addition, the efficacy of these newer quinolones has been studied in animal models of pneumonia, endocarditis, meningitis, skin and soft tissue infections, and a variety of other systemic infections. Although certain limitations are associated with animal models of infection, properly performed studies clearly have the potential to provide guidelines for evaluating the efficacy of antimicrobial agents in the treatment of some infections in humans.

UI	MeSH Term	Description	Entries
D011804	Quinolines
D002939	Ciprofloxacin	A broad-spectrum antimicrobial carboxyfluoroquinoline.	Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004195	Disease Models, Animal	Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004353	Drug Evaluation, Preclinical	Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.	Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D000900	Anti-Bacterial Agents	Substances that inhibit the growth or reproduction of BACTERIA.	Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001424	Bacterial Infections	Infections by bacteria, general or unspecified.	Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases

Related Publications

V T Andriole

Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia.

April 1987, The American journal of medicine,

V T Andriole

Animal models: the in-vivo evaluation of ciprofloxacin.

November 1986, The Journal of antimicrobial chemotherapy,

V T Andriole

Decontaminating efficacy of ciprofloxacin in an animal model.

October 1989, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,

V T Andriole

Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection.

October 2022, Scientific reports,

V T Andriole

Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation.

April 2021, Antibiotics (Basel, Switzerland),

V T Andriole

Therapeutic efficacy of ozenoxacin in animal models of dermal infection with Staphylococcus aureus.

May 2018, Future microbiology,

V T Andriole

Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.

August 2002, Antimicrobial agents and chemotherapy,